Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Langley

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|August 30, 2005
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitorsJoseph Yanchunas, David R Langley, Li Tao, et al.
Protein Science : a Publication of the Protein Society|March 19, 2014
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitorsSebastian M Lambert, David R Langley, James A Garnett, et al.
Journal of Chemical Information and Modeling|January 30, 2025
Accurate Physics-Based Prediction of Binding Affinities of RNA- and DNA-Targeting LigandsAra M Abramyan, Anna Bochicchio, Chuanjie Wu, et al.
Proteins|November 18, 2014
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of actionDavid R Langley, S Roy Kimura, Prasanna Sivaprakasam, et al.
The Journal of Biological Chemistry|August 24, 2007
Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitorsIra B Dicker, Himadri K Samanta, Zhufang Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligandsRichard A Hartz, Argyrios G Arvanitis, Charles Arnold, et al.
Journal of Virology|June 1, 2007
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavirHerbert E Klei, Kevin Kish, Pin-Fang M Lin, et al.
Journal of Virology|February 3, 2007
Inhibition of hepatitis B virus polymerase by entecavirDavid R Langley, Ann W Walsh, Carl J Baldick, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2004
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusionChristopher Cianci, David R Langley, Douglas D Dischino, et al.
Journal of Medicinal Chemistry|December 23, 2017
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug FostemsavirNicholas A Meanwell, Mark R Krystal, Beata Nowicka-Sans, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|August 30, 2005
Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitorsJoseph Yanchunas, David R Langley, Li Tao, et al.
Protein Science : a Publication of the Protein Society|March 19, 2014
The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitorsSebastian M Lambert, David R Langley, James A Garnett, et al.
Journal of Chemical Information and Modeling|January 30, 2025
Accurate Physics-Based Prediction of Binding Affinities of RNA- and DNA-Targeting LigandsAra M Abramyan, Anna Bochicchio, Chuanjie Wu, et al.
Proteins|November 18, 2014
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of actionDavid R Langley, S Roy Kimura, Prasanna Sivaprakasam, et al.
The Journal of Biological Chemistry|August 24, 2007
Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitorsIra B Dicker, Himadri K Samanta, Zhufang Li, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligandsRichard A Hartz, Argyrios G Arvanitis, Charles Arnold, et al.
Journal of Virology|June 1, 2007
X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavirHerbert E Klei, Kevin Kish, Pin-Fang M Lin, et al.
Journal of Virology|February 3, 2007
Inhibition of hepatitis B virus polymerase by entecavirDavid R Langley, Ann W Walsh, Carl J Baldick, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2004
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusionChristopher Cianci, David R Langley, Douglas D Dischino, et al.
Journal of Medicinal Chemistry|December 23, 2017
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug FostemsavirNicholas A Meanwell, Mark R Krystal, Beata Nowicka-Sans, et al.
Pageof 6